Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 13

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 13
---
 Representative’s’ 
 over-allotment option;               |

| ● | no exercise of Representative’s 
 Warrants;                       |

| ● | the automatic conversion                                                                                                          
 of all outstanding preferred shares, no par value, of the Company, or the Preferred Shares, into 2,603,652 Ordinary Shares, which 
 will occur upon the completion of this offering;                                                                                  |

| ● | the issuance of 609,888                                                                                                                    
 Ordinary Shares issuable upon the automatic conversion of the $900,000 outstanding principal amount of several convertible loan agreements 
 entered into between August 2020 and February 2021, or the 2020 CLAs, which will occur upon the completion of this offering; and           |

| ● | the issuance of 553,640                                                                                                                    
 Ordinary Shares issuable upon the automatic conversion of the $450,000 outstanding principal amount of several convertible loan agreements 
 entered into in October 2024, or the 2024 CLAs, including related risk premium, which will occur upon the completion of this offering.     |

See “Description of Share Capital” for additional information.

<div align='center'>12</div>

SUMMARY FINANCIAL DATA The following table summarizes our financial data. We have derived the following statements of comprehensive loss for the years ended December 31, 2024 and 2023 the balance sheet data as of December 31, 2024 from our audited financial statements. Such financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles, or U.S GAAP. Our historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial data should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and related notes included elsewhere in this prospectus.

| (in thousands of USD, except share                                       
 and per share data)                                                      |     | Year         
 Ended        
 December 31, 
 2024         |           |   |     | 2023 |         |   |
|:-------------------------------------------------------------------------|:----|:-------------|----------:|:--|:----|:-----|--------:|:--|
| Statements of comprehensive loss:                                        |     |              |           |   |     |      |         |   |
| Research and development expenses:                                       |     |              |           |   |     |      |         |   |
| Horizon                                                                  
 2020 Grant                                                               |